Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2431 to 2445 of 7681 results

  1. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026]

    In development [GID-TA10918] Expected publication date: 11 December 2024

    Technology appraisal guidance
    In development

  2. Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]

    In development [GID-TA11485] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  3. Teprotumumab for treating thyroid eye disease [ID6432]

    In development [GID-TA11531] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  4. Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention

    In development [GID-IPG10391] Expected publication date: 05 February 2025

    Interventional procedures guidance
    In development

  5. Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

    In development [GID-TA11232] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  6. Ovarian cancer QS update

    In development [GID-QS10182] Expected publication date: 05 February 2025

    Quality standard
    In development

  7. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 20 November 2024.

    Technology appraisal guidance
    In consultation

  8. Vosoritide for treating achondroplasia in people 4 months and over ID6488

    Awaiting development [GID-TA11528] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. One-piece closed bags for adults with a colostomy: Late Stage Assessment

    In development [GID-HTE10045] Expected publication date: TBC

    Health technology evaluations
    In development

  10. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development [GID-TA10911] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Robot-assisted surgery for orthopaedic procedures: early value assessment

    In development [GID-HTE10043] Expected publication date: 31 March 2025

    Health technology evaluations
    In development

  12. Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]: evaluation consultation

    We are listening to your views on this Highly specialised technology. Comments close 21 November 2024.

    Highly specialised technologies guidance
    In consultation

  13. Exagamglogene autotemcel for treating sickle cell disease [ID4016]

    In development [GID-TA11249] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423

    In development [GID-TA11431] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  15. Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis ID6458

    Awaiting development [GID-TA11477] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development